Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma

Joint Bone Spine

Volumn 84, Issue 2, 2017, Pages 233-234

  Garel, Bethsabée ^a,b   Kramkimel, Nora ^a,b   Trouvin, Anne Priscille ^a,b   Frantz, Camélia ^a,b   Dupin, Nicolas ^a,b  

^a Assistance publique–Hôpitaux de Paris ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Anti PD 1 antibody; Melanoma; Pembrolizumab; Polymyalgia rheumatica

Indexed keywords

C REACTIVE PROTEIN; DACARBAZINE; PEMBROLIZUMAB; PREDNISONE; MONOCLONAL ANTIBODY;

AGED; CASE REPORT; DISEASE SEVERITY; FEMALE; HUMAN; LETTER; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; PROGNOSIS; RHEUMATIC POLYMYALGIA; SYMPTOMATOLOGY; TREATMENT RESPONSE; VERY ELDERLY; CANCER STAGING; CHEMICALLY INDUCED; EPIDEMIOLOGY; FOLLOW UP; MELANOMA; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RARE DISEASE; RISK ASSESSMENT; SKIN TUMOR; TREATMENT OUTCOME; TUMOR INVASION; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POLYMYALGIA RHEUMATICA; RARE DISEASES; RISK ASSESSMENT; SAMPLING STUDIES; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84964240504     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2016.01.007     Document Type: Letter

References (7)

1. [1] Ribas, A., Puzanov, I., Dummer, R., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16 (2015), 908–918.
2. [2] Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
3. [3] Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
4. [4] Dasgupta, B., Cimmino, M.A., Maradit-Kremers, H., et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71 (2012), 484–492.
5. [5] Goldstein, B.L., Gedmintas, L., Todd, D.J., Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 66 (2014), 768–769.
6. [6] Chan, M.M.K., Kefford, R.F., Carlino, M., et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 38 (2015), 37–39.
7. [7] Sanlorenzo, M., Vujic, I., Daud, A., et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151 (2015), 1206–1212.